DiabetesRes Clin Pract:持续不卧床腹透有效可靠

2013-05-09 佚名 医师报

  中山大学第一附属医院肾内科余学清教授等公布的一项为期5 年的临床队列研究表明, 在我国接受持续性不卧床腹膜透析(CAPD)的患者中,糖尿病并不显著影响生存率。对于接受CAPD 的糖尿病患者,启动CAPD 时高龄、合并心血管疾病、血糖水平较高、贫血和低白蛋白血症均是影响生存率的因素。(DiabetesRes Clin Pract.&nb

  中山大学第一附属医院肾内科余学清教授等公布的一项为期5 年的临床队列研究表明, 在我国接受持续性不卧床腹膜透析(CAPD)的患者中,糖尿病并不显著影响生存率。对于接受CAPD 的糖尿病患者,启动CAPD 时高龄、合并心血管疾病、血糖水平较高、贫血和低白蛋白血症均是影响生存率的因素。(DiabetesRes Clin Pract. 2013 年4 月22 日在线版)

  该纵向队列研究入选809例接受CAPD 的肾病患者,其中189 例(23.4%)合并糖尿病。研究者报告,糖尿病患者和非糖尿病患者的死亡审查技术(Death-censored technique)生存率无显著差异(P=0.271)。然而, 糖尿病患者1、2、3、5 年生存率依次为90%、72%、63% 和36%,非糖尿病组则依次为95%、92%、87% 和73%(P=0.000)。在启动CAPD 时,合并心血管疾病(HR=2.130,P=0.010)、高龄(HR=1.042,P=0.014)、糖化血红蛋白水平较高(HR=1.309,P=0.019)、低白蛋白血症(HR=0.924,P=0.004) 和血红蛋白水平降低(HR=0.978,P=0.003)均是糖尿病患者死亡的独立预测因素。

  研究者观点

  有关糖尿病腹透患者的生存率,美国USRDS 研究中患者1、3、5 年生存率依次为87.4%、54.9% 和34.8%;韩国男、女性患者3 年生存率分别为70% 和46%;我国台湾地区5 年生存率仅为26%;加拿大患者1、3、5 年生存率为91%、66% 和47%。我国患者1、3、5 年生存率依次为90%、63% 和36%,说明在基于血糖的腹透技术治疗下,我国糖尿病患者的生存率优于上述国家或地区。因此,对我国合并糖尿病的终末期肾病患者来说,CAPD 是长期肾脏替代治疗的可靠治疗模式。

腹透相关的拓展阅读:


Clinical outcome and risk factors for mortality in Chinese patients with diabetes on peritoneal dialysis: A 5-year clinical cohort study.
AIMS
We evaluated clinical outcome and risk factors affecting survival in patients with diabetes on continuous ambulatory peritoneal dialysis (CAPD) in Southern China.
METHODS
This longitudinal cohort study enrolled all incident patients who used CAPD as their first renal replacement therapy modality in our center from January 2006 to December 2009 and who were followed until December 2011. Clinical outcomes were compared and risk factors for mortality in patients with diabetes were analyzed.
RESULTS
Of 809 incident CAPD patients, 189 (23.4%) had diabetes. Death-censored technique survival showed no significant difference between patients with and without diabetes (p=0.271). The 1-, 2-, 3- and 5-year patient survival rates were 90%, 72%, 63% and 36% in patients with diabetes and 95%, 92%, 87% and 73% in patients without diabetes, respectively (p=0.000). Presence of cardiovascular disease (CVD) [hazard ratio (HR) 2.130, 95% confidence interval (CI) 1.199-3.786, p=0.010], advanced age (HR 1.042, 95% CI 1.008-1.078, p=0.014), higher glycated hemoglobin (HR 1.309, 95% CI 1.045-1.640, p=0.019), lower hemoglobin (HR 0.978, 95% CI 0.964-0.992, p=0.003) and lower serum albumin (HR 0.924, 95% CI 0.876-0.976, p=0.004) at the initiation of CAPD were independent risk factors of mortality in CAPD patients with diabetes.
CONCLUSIONS
Technique survival in CAPD patients with diabetes was similar to those without diabetes. Although patients with diabetes had higher risk of mortality, the patient survival in our study seems to be improved compared with most other reports. Older age, presence of CVD, hyperglycemia, anemia and hypoalbuminemia at the commencement of CAPD affected survival in patients with diabetes.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1901088, encodeId=39dc19010888d, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Mar 31 12:17:00 CST 2014, time=2014-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759283, encodeId=14b11e5928323, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Feb 23 17:17:00 CST 2014, time=2014-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636669, encodeId=2cfd1636669a2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 07 19:17:00 CST 2014, time=2014-01-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1901088, encodeId=39dc19010888d, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Mar 31 12:17:00 CST 2014, time=2014-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759283, encodeId=14b11e5928323, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Feb 23 17:17:00 CST 2014, time=2014-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636669, encodeId=2cfd1636669a2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 07 19:17:00 CST 2014, time=2014-01-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1901088, encodeId=39dc19010888d, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Mar 31 12:17:00 CST 2014, time=2014-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759283, encodeId=14b11e5928323, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Feb 23 17:17:00 CST 2014, time=2014-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636669, encodeId=2cfd1636669a2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 07 19:17:00 CST 2014, time=2014-01-07, status=1, ipAttribution=)]

相关资讯

Kidney Int:130~159 mmHg或为更佳透析前收缩压

  一项多国联合研究显示,透析前收缩压在 130~159 mmHg的肾病患者死亡率最低,提示其可能为最佳收缩压范围。这一结论与改善全球肾病预后组织(KDIGO)制定的透析前血压<140/90 mmHg的目标存在差异,因此,该研究结果有助于为寻找最佳血压范围提供指导。论文发表于《国际肾脏》(Kidney Int. 2012 Sep;82(5):570-80.)杂志。     研究纳入2

探讨透析患者的调脂治疗

作者:北京大学第一医院肾内科 北京大学肾脏病研究所 许戎 董捷        透析患者的血脂异常发生率显著高于一般人群。患者主要表现为甘油三酯(TG)水平升高、高密度脂蛋白胆固醇(HDL-C)水平下降,总胆固醇(TC)及低密度脂蛋白胆固醇(LDL-C)水平在血液透析(简称血透)患者中可正常甚至下降,在腹膜透析(简称腹透)患者中却升高。然而,在透析患者中,关

JCE :导管消融可用于长期透析伴阵发性房颤患者

  房颤在长期透析患者中十分常见,有报道显示13%-27%的长期透析患者合并房颤,而且合并房颤者的死亡率显着高于不合并房颤者。在临床实践中,一旦在透析过程中发作快心室率房颤,往往需要调整血透模式,甚至因为血流动力学异常和严重的心悸症状而停止血透。另外由于多数抗心律失常药物需要经过肾脏排泄,抗心律失常药物对慢性透析合并房颤患者的安全性和有效性都明显降低,因此这些患者需要一种新的治疗方法。   导管

Diabetes Care:靶向HbA1c改善透析糖尿病患者死亡率

      欧美学者的透析转归和实践特征研究(DOPPS)的最新结果表明,在伴有1型或2型糖尿病的透析患者中糖化血红蛋白(HbA1c)水平强烈预测患者死亡率。HbA1c在7%~7.9%区间之外时死亡率升高,因而,调整透析患者降糖治疗药物可作为改善转归的临床实践。论文于2012年8月21日在线发表于《糖尿病护理》(Diabetes Care)杂志。    此项研究共纳入9201例伴有1型或2型糖

JASN:经导管透析者死亡率高

  加拿大学者经检索Medline、Embase等数据库,共纳入67项研究的一项系统综述显示,与使用动静脉瘘和动静脉移植物者相比,经中心静脉导管透析者的全因死亡率[危险度(RR)=1.53,RR=1.38]、致死性感染(RR=2.12,RR=1.49)和心血管事件(RR=1.38, RR=1.26)发生风险均较高。与使用动静脉瘘者相比,使用移植物者的全因死亡率(RR=1.18)和致死性感

Am J Kidney Dls:降糖药物或使肾病透析患者获益

  美国一项随机双盲试验显示,对于2型糖尿病和接受透析治疗的终末期肾脏病(ESRD)患者,使用西格列汀或格列吡嗪单药治疗54周以上有效且耐受性良好。   该研究纳入年龄为30岁及以上罹患2型糖尿病和接受透析治疗的ESRD 者129例,且糖化血红蛋白(HbAlc)为7%、9%,将其按1:1随机分为西格列汀组(n=64,25 tng/d,平均年龄为61岁,Hb/Uc为7.&nbs